All stock lists
OKYO Pharma Ltd (NASDAQ:OKYO)
GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.42+0.02 (+1.43%)
Market cap
$74.5M
Health Score
Analyst consensus
Listed since
May 17, 2022
Website
Insider Score
––Not scored
OKYO Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Sound
From OKYO’s reported statements · Q1 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$13.7M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $14.6M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $21.0M
- Current liabilities
- $8.6M
- Current ratio
- 2.43
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$7.7M
- Free cash flow
- -$7.8M
Dilution & runway9 / 20
Some dilution over the past year.
- Shares outstanding
- 37.4M
- Share growth (1y)
- 13.4%
- Cash runway
- 23 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
OKYO Income Statement
| Fiscal Period | Q1 2026 | Q3 2025 | Q1 2025 | Q4 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|
| Period Ending | Mar 31, 2026 | Sep 30, 2025 | Mar 31, 2025 | Oct 1, 2024 | Mar 31, 2024 | Oct 1, 2023 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 935.00 | 885.00 | 1.29 K | 0.00 | 3.37 K | 2.08 K |
| Gross Profit | -935.00 | -885.00 | -1.29 K | 0.00 | -3.37 K | -2.08 K |
| SG&A Expense | 4.55 M | 2.84 M | 4.14 M | 791.71 K | 0.00 | 4.11 M |
| R&D Expense | 1.85 M | -44.05 K | 38.37 K | 2.22 M | 3.64 K | 4.60 M |
| Operating Expenses | 6.41 M | 2.79 M | 4.18 M | 3.01 M | 3.64 K | 8.71 M |
| Operating Income | -6.41 M | -2.79 M | -4.18 M | -3.01 M | -7.01 K | -8.71 M |
| Pretax Income | -6.35 M | -2.59 M | -3.87 M | -4.10 M | -8.06 K | -8.73 M |
| Tax Provision | 7.93 K | 52.00 | -1.85 M | -1.42 M | 60.41 | 82.83 K |
| Net Income | -6.36 M | -2.59 M | -2.03 M | -2.68 M | -8.12 K | -8.82 M |
| EPS (Basic) | -0.17 | -0.07 | -0.04 | -0.08 | -0.00 | -0.00 |
| EPS (Diluted) | -0.17 | -0.07 | -0.04 | -0.08 | -0.00 | -0.00 |
| Shares Outstanding | 37.39 M | 37.42 M | 39.49 M | 33.57 M | 32.97 M | 25.71 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.